Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Concord Drugs Ltd indicates a balanced view of the stock’s prospects. It suggests that while the company shows potential in certain areas, investors should exercise caution and monitor developments closely before making significant portfolio adjustments. This rating reflects a moderate confidence level, implying that the stock may neither significantly outperform nor underperform the broader market in the near term.
Quality Assessment
As of 27 June 2026, Concord Drugs Ltd’s quality grade is assessed as below average. This is primarily due to its weak long-term fundamental strength. The company’s average Return on Capital Employed (ROCE) stands at 5.41%, which is modest and indicates limited efficiency in generating profits from its capital base. Over the past five years, net sales have grown at an annual rate of 14.78%, but operating profit growth has lagged significantly at just 2.53% annually. Furthermore, the company’s ability to service debt is constrained, with an average EBIT to interest ratio of 1.56, signalling potential vulnerability to interest rate fluctuations or increased borrowing costs.
Valuation Perspective
Despite the quality concerns, Concord Drugs Ltd’s valuation grade is considered attractive. The stock trades at a discount relative to its peers’ historical valuations, with an Enterprise Value to Capital Employed ratio of 1.8. This suggests that the market currently prices the company conservatively, potentially offering value to investors willing to accept the associated risks. The company’s PEG ratio of 0.7 further supports this view, indicating that its price-to-earnings ratio is low relative to its earnings growth, which is a positive signal for value-oriented investors.
Financial Trend and Recent Performance
The financial grade for Concord Drugs Ltd is very positive, reflecting strong recent earnings momentum. As of 27 June 2026, the company reported a remarkable 1,225% growth in net profit, with quarterly figures showing the highest Profit Before Tax (PBT) excluding other income at ₹0.75 crore and the highest quarterly PAT at ₹0.53 crore. Net sales for the quarter also reached a record ₹37.90 crore. This surge in profitability contrasts with the more modest long-term growth trends and highlights a potential turnaround or operational improvement in recent months.
Technical Outlook
From a technical standpoint, the stock is mildly bullish. The latest price movements show a 1-day gain of 1.61%, although short-term returns over one week and one month have been slightly negative at -0.78% and -2.03%, respectively. Over three months, the stock has appreciated by 6.70%, but it has experienced a 9.46% decline over six months and a 7.37% drop year-to-date. Despite these fluctuations, the stock’s one-year return is an impressive 146.45%, significantly outperforming the BSE500 index, which has declined by 1.13% over the same period. This market-beating performance underscores the stock’s potential for investors with a higher risk tolerance.
Shareholding and Market Capitalisation
Concord Drugs Ltd remains a microcap company within the Pharmaceuticals & Biotechnology sector, with promoters holding the majority stake. This concentrated ownership can be a double-edged sword, offering stability but also limiting liquidity and increasing exposure to promoter-related risks.
Summary for Investors
In summary, Concord Drugs Ltd’s 'Hold' rating reflects a nuanced picture. The company’s recent financial results are encouraging, with strong profit growth and record sales suggesting operational improvements. However, the underlying quality metrics and long-term fundamentals remain below average, and the stock’s valuation, while attractive, signals market caution. Investors should weigh these factors carefully, considering their investment horizon and risk appetite. The mildly bullish technical indicators and significant one-year returns may appeal to those seeking growth opportunities in the pharmaceutical microcap space, but the inherent volatility and fundamental challenges warrant a measured approach.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Contextualising Returns and Market Comparison
It is important to note that Concord Drugs Ltd’s stock has delivered exceptional returns over the past year, with a gain of 146.45% as of 27 June 2026. This performance is particularly notable given the broader market environment, where the BSE500 index has declined by 1.13% during the same period. Such outperformance highlights the stock’s potential as a market-beating investment, albeit with the caveat of its microcap status and associated risks.
Financial Metrics in Detail
The company’s financial health is further illustrated by its quarterly results. The highest quarterly Profit Before Tax excluding other income reached ₹0.75 crore, while the highest quarterly PAT was ₹0.53 crore. Net sales for the quarter peaked at ₹37.90 crore, signalling robust operational activity. These figures demonstrate a strong upward trend in profitability, which is a key factor supporting the current 'Hold' rating.
Valuation and Growth Prospects
Concord Drugs Ltd’s valuation metrics remain attractive, with an Enterprise Value to Capital Employed ratio of 1.8, suggesting the stock is reasonably priced relative to its capital base. The PEG ratio of 0.7 indicates that the stock’s price is low compared to its earnings growth rate, which is a positive sign for investors seeking value combined with growth potential. However, investors should remain mindful of the company’s below-average quality grade and moderate long-term growth rates when considering their investment decisions.
Conclusion
Overall, Concord Drugs Ltd’s 'Hold' rating by MarketsMOJO reflects a balanced assessment of the company’s current standing. While recent financial trends and valuation metrics offer reasons for cautious optimism, the underlying quality and long-term fundamentals suggest that investors should maintain a watchful stance. This rating advises neither aggressive buying nor selling but rather a prudent approach, monitoring the company’s progress and market conditions closely.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
